C

Claritas Pharmaceuticals Inc
XTSX:CLAS

Watchlist Manager
Claritas Pharmaceuticals Inc
XTSX:CLAS
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: CA$10.4m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Claritas Pharmaceuticals Inc
XTSX:CLAS
10.4m CAD
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
271.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.2B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.1B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.6B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Claritas Pharmaceuticals Inc
Glance View

Market Cap
10.4m CAD
Industry
Pharmaceuticals

Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in Novato, California. The company went IPO on 2005-05-19. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.

CLAS Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top